Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identification and evaluation of novel therapeutics for myotubular myopathy
EF 2014-15
Résumé
Myotubular myopathy is a rare disorder affecting skeletal muscle that is caused by mutations in the gene MTM1 . Affected individuals are predominantly male who present with severe phenotypes at birth such as hypotonia, respiratory insufficiency, and high rates of neonatal mortality. There are currently no drug therapies available to treat this devastating disorder. Hence, the overarching goal of my research is to identify the first therapeutic drug leads with potential to treat myotubular myopathy. It has been observed that skeletal muscle-specific knockout of the gene PIK3C2B in an MTM1 null mutant mouse - a model for myotubular myopathy - is able to rescue these mice from early lethality and, strikingly, extend their lifespan to wild-type levels. Meanwhile, whole body knockout of PIK3C2B in wild-type mice has no observable adverse effects on either development or lifespan. This data indicates that pharmacological inhibitors of PIK3C2B have potential to be highly effective in the treatment of myotubular myopathy. My first goal is to test molecules that inhibit PIK3C2B for efficacy in rescuing the MTM1 mutant phenotype in the zebrafish D. rerio . Testing molecules for efficacy in zebrafish is more time- and cost-effective than testing them first in mice. Secondly, my goal is to identify previously uncharacterized molecules that can rescue the MTM1 mutant phenotype in the nematode C. elegans and once again test these in the zebrafish model of MTM1 .This unbiased approach has the advantage of revealing potentially novel mechanisms involved in the pathogenesis of this disorder. In the future, promising molecules that rescue the MTM1 mutant phenotype in zebrafish will be tested for therapeutic value in the MTM1 mouse and patient myofibers.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331538
Name
Volpatti Jonathan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and evaluation of novel therapeutics for myotubular myopathy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Models Of Disease; Centronuclear Myopathy; Chemical And Genetic Screens; Congenital Disorder; Drug Discovery; Myotubular Myopathy; Phosphatidylinositol 3-Phosphate; Phosphoinositide Signalling; Rare Disease; Translational Research
Abstract
Myotubular myopathy is a rare disorder affecting skeletal muscle that is caused by mutations in the gene MTM1 . Affected individuals are predominantly male who present with severe phenotypes at birth such as hypotonia, respiratory insufficiency, and high rates of neonatal mortality. There are currently no drug therapies available to treat this devastating disorder. Hence, the overarching goal of my research is to identify the first therapeutic drug leads with potential to treat myotubular myopathy. It has been observed that skeletal muscle-specific knockout of the gene PIK3C2B in an MTM1 null mutant mouse - a model for myotubular myopathy - is able to rescue these mice from early lethality and, strikingly, extend their lifespan to wild-type levels. Meanwhile, whole body knockout of PIK3C2B in wild-type mice has no observable adverse effects on either development or lifespan. This data indicates that pharmacological inhibitors of PIK3C2B have potential to be highly effective in the treatment of myotubular myopathy. My first goal is to test molecules that inhibit PIK3C2B for efficacy in rescuing the MTM1 mutant phenotype in the zebrafish D. rerio . Testing molecules for efficacy in zebrafish is more time- and cost-effective than testing them first in mice. Secondly, my goal is to identify previously uncharacterized molecules that can rescue the MTM1 mutant phenotype in the nematode C. elegans and once again test these in the zebrafish model of MTM1 .This unbiased approach has the advantage of revealing potentially novel mechanisms involved in the pathogenesis of this disorder. In the future, promising molecules that rescue the MTM1 mutant phenotype in zebrafish will be tested for therapeutic value in the MTM1 mouse and patient myofibers.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Volpatti, Jonathan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~